Differential regulation by AT 1 and AT 2 receptors of angiotensin II-stimulated cyclic GMP production in rat uterine artery and aorta

Department of Pharmacology, Monash University, Clayton, Victoria 3800, Australia.
British Journal of Pharmacology (Impact Factor: 4.84). 04/2004; 141(6):1024-31. DOI: 10.1038/sj.bjp.0705694
Source: PubMed


In the present study we determined whether angiotensin II (Ang II) could increase cyclic GMP levels in two blood vessels that exhibit markedly different angiotensin II receptor subtype expression: rat uterine artery (UA; AT2 receptor-predominant) and aorta (AT1 receptor-predominant), and investigated the receptor subtype(s) and intracellular pathways involved.
UA and aorta were treated with Ang II in the absence and presence of losartan (AT1 antagonist; 0.1 μM), PD 123319 (AT2 antagonist; 1 μM), NOLA (NOS inhibitor; 30 μM), and HOE 140 (B2 antagonist; 0.1 μM), or in combination.
Ang II (10 nM) induced a 60% increase in UA cyclic GMP content; an effect that was augmented with PD 123319 and HOE 140 pretreatment, and abolished by cotreatment with losartan, as well as by NOLA.
In aorta, Ang II produced concentration-dependent increases in cyclic GMP levels. Unlike effects in UA, these responses were abolished by PD 123319 and by NOLA, whereas losartan and HOE 140 caused partial inhibition.
Thus, in rat UA, Ang II stimulates cyclic GMP production through AT1 and, to a less extent, AT2 receptors. In rat aorta, the Ang II-mediated increase in cyclic GMP production is predominantly AT2 receptor-mediated. In both preparations, NO plays a critical role in mediating the effect of Ang II, whereas bradykinin has differential roles in the two vessels. In UA, B2 receptor blockade may result in a compensatory increase in cyclic GMP production, whilst in aorta, bradykinin accounts for approximately half of the cyclic GMP produced in response to Ang II.
British Journal of Pharmacology (2004) 141, 1024–1031. doi:10.1038/sj.bjp.0705694


Available from: Robert E Widdop
  • Source
    • "It demonstrated that (1) lower angiotensin AT 2 receptors (AT 2 R) mRNA and protein expression can contribute to vasoconstriction in untreated SHR; (2) acute and chronic AT 1 -blockade restored AT 2 R expression and its vasodilator function in mesenteric resistance arteries and contributes to blood pressure control in SHR treated (You et al., 2005; Badzynska et al., 2014). Vasodilation induced by AT 2 R stimulation has been associated with NO production by endothelial cells and cGMP production by smooth muscle cells (Hannan et al., 2004). "
    [Show abstract] [Hide abstract]
    ABSTRACT: This work investigated the effects of the ethanolic extract (EEJg) of aerial parts of Jatropha gossypiifolia L. and its aqueous (AFJg) and chloroformic (CFJg) fractions on the blood pressure and vascular reactivity (VR) in normotensive Wistar rats (NWR) and spontaneously hypertensive rats (SHR). In anaesthetized NWR, the EEJg and its fractions reduced mean blood pressure (MAP). The oral administration of EEJg (100 mg/kg/bw), for 8 weeks, did not alter MAP and heart rate in the non-anesthetized SHR. VR was determined in mesenteric artery rings, with the EEJg and fractions inhibiting the contractile responses to noradrenaline (NA, 10-9 to 10-4 M) in NWR, but not in SHR. In addition, the CFJg inhibited the contractile response to calcium (CaCl 2 , 10-6 to 10-2 M). These results suggest that J. gossypiifolia L. has no effect on the hypertensive factors in SHR, which is a model of polygenic hypertension, but indicate the presence of substances with hypotensive activity, which act directly on the adrenoceptor and/or decrease calcium mobilization in NWR.
    African journal of pharmacy and pharmacology 04/2014; 9(11):375-382. · 0.84 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: British Journal of Pharmacology (2003) 140, 809–824. doi:10.1038/sj.bjp.0705448
    British Journal of Pharmacology 12/2003; 140(5):809-24. DOI:10.1038/sj.bjp.0705448 · 4.84 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We have previously shown that angiotensin II type 2 receptor (AT(2)R) stimulation causes endothelium-dependent vasodilation that does not desensitize after chronic angiotensin II type 1 receptor (AT1R) blockade, suggesting a role for AT2R in antihypertensive treatment. We recorded mean arterial pressure (MAP) and investigated AT2R by Western blot analysis, immunohistochemistry, and function in isolated mesenteric resistance arteries (205 microm in diameter) from Wistar-Kyoto (WKY) rats and spontaneously hypertensive rats (SHR) receiving the following for 4 weeks in drinking water: placebo, AT1R blockade (candesartan; 2 mg/kg per day), ACE inhibitor (perindopril; 3 mg/kg per day), nonselective vasodilator (hydralazine; 16 or 24 mg/kg per day), or candesartan plus hydralazine (16 mg/kg per day). In precontracted isolated arteries, AT2R stimulation (angiotensin II in the presence of candesartan) caused vasodilation in WKY rats (MAP=118 mm Hg) and vasoconstriction in SHR (MAP=183 mm Hg). In SHR treated with candesartan (MAP=146 mm Hg) or hydralazine (16 mg/kg per day; MAP=145 mm Hg), AT2R-induced contraction was reduced by 50%. In SHR treated with perindopril (MAP=125 mm Hg), AT2R stimulation induced vasodilation. In SHR treated with hydralazine (24 mg/kg per day; MAP=105 mm Hg) and in SHR treated with hydralazine (16 mg/kg per day) plus candesartan (MAP=102 mm Hg), an AT2R-mediated vasodilation was restored. Immunochemistry and Western blot analysis showed that AT2R expression, lower in SHR than in WKY rats, was restored to normal levels by treatments reducing arterial pressure in SHR. Our results suggest that in resistance arteries of SHR, (1) AT2R is downregulated by hypertension, and (2) specific and nonspecific antihypertensive treatments restore AT(2)R expression and vasodilator functions.
    Circulation 04/2005; 111(8):1006-11. DOI:10.1161/01.CIR.0000156503.62815.48 · 14.43 Impact Factor
Show more